Day: August 12, 2021

First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 PALO ALTO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “During the past quarter, we achieved an important milestone in dosing the first patient in our Phase 1b study of VIP152, our selective PTEFb/CDK9 inhibitor, in MYC-driven indications, building upon the compelling signals of monotherapy...

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) — Ideal Power Inc. (“Ideal Power” or the “Company”) (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, reported results for its second quarter ended June 30, 2021. “Our recent announcements of test and evaluation collaborations with leaders in the electric vehicle (EV), uninterruptible power supplies (UPS) for data centers and renewable energy markets represent the launch of our commercialization of B-TRAN™,” stated Dan Brdar, President and Chief Executive Officer of Ideal Power. “These customer engagements are a crucial step forward in establishing B-TRAN™ as a differentiated semiconductor architecture technology addressing a large and growing market. We are also partnering with Diversified...

Urban Delivery is on track to be the first Class 1 commercial electric vehicle in the U.S., with start of production confirmed for the third quarter this year. Continued strong demand for the Urban Delivery and actively working to finalize order commitments. Completed business combination to become a publicly traded company, with approximately $294 million of capital raised. Acquired EV manufacturing facility with up to 100,000-unit annual capacity in Mishawaka, Indiana. Strategic supply chain in place, production schedule set for 2021 with an updated volume target of 1,000 units. ELMS engineering center established and staffed for vehicle integration, design and launch of commercial EV products.TROY, Mich., Aug. 12, 2021 (GLOBE NEWSWIRE) — Electric Last Mile Solutions, Inc. (NASDAQ: ELMS; ELMSW) (“ELMS” or the “Company”), a...

Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 Accessions New Publication Demonstrates OVA1 Superiority to Standard of Care Expanded Access of OVA1 Through AIM Specialty Health Conference Call and Webcast Today at 4:30 p.m. ET AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended, June 30, 2021. “We are pleased with the volume growth in our products as the economy has somewhat emerged from COVID-19 restriction as well as with the advancement of our preparations for our fourth quarter 2021 launch of OVASight,” indicated Valerie Palmieri, Chief Executive Officer. “We are making positive progress on our product collaboration...

Total Revenue up 90%, Gross Profit Increases by 99%, and Backlog Grows to a Record $17.0 Million TEMPE, Ariz. , Aug. 12, 2021 (GLOBE NEWSWIRE) — VirTra, Inc. (NASDAQ: VTSI) (“VirTra”), a global provider of training simulators for the law enforcement, military, educational and commercial markets, reported results for the second quarter and six months ended June 30, 2021. The financial statements are available on VirTra’s website and here. Second Quarter 2021 Financial Highlights:Total revenue increased 90% to $5.3 million Gross profit increased 99% to $3.1 million, or 60% of total revenue Net income increased to $529,400 Adjusted EBITDA increased to $1.0 million Backlog increased 6% sequentially and 19% year-over-year to a record $17.0 million as of June 30, 2021 Unrestricted cash and cash equivalents totaled $23.8 millionSix...

Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2021. Financial and Operating Highlights:Revenue increased 37.5% to $4.5 million for the second quarter of 2021 and was $7.9 million for the six months ended June 30, 2021, compared to $3.3 million and $6.5 million for the three and six months ended...